Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Thromboembolic Disease Clear all
Completed No phase listed Observational

Heparin or Enoxaparin in Patients With Cancer

NCT00004875
View directory record Official record
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Jul 21, 2026, 1:46 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

129Xe MRI Cardiopulmonary

NCT06038630
View directory record Official record
Conditions
Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
Interventions
Hyperpolarized Xe129, Oxygen Administration
Drug · Other
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 21, 2026, 1:46 PM EDT
Recruiting No phase listed Observational

Chronic Thromboembolic Disease Registry

NCT05843500
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, Chronic Thromboembolic Disease
Interventions
Survey
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.

NCT01884675
View directory record Official record
Conditions
Hypertension
Interventions
Ambrisentan 5 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 21, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

NCT00910429
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
8
States / cities
La Jolla, California • Sacramento, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators

NCT02111980
View directory record Official record
Conditions
Cardiomyopathy, Cardiac Arrhythmia, Heart Failure, Chronic Thromboembolic Pulmonary Hypertension
Interventions
RF Assure Scanning
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Jul 21, 2026, 1:46 PM EDT
No Longer Available No phase listed Expanded access

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT01784562
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Adempas (Riociguat, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Jul 21, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

NCT00855465
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jul 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 21, 2026, 1:46 PM EDT
Not listed Phase 2Phase 3 Interventional

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

NCT00691470
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
Interventions
ATI-5923, Coumadin (warfarin)
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Jul 21, 2026, 1:46 PM EDT
Completed No phase listed Observational

U.S. CTEPH Registry

NCT02429284
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jul 21, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

NCT02981472
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
28 Days to 17 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Jul 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension in Patients With Prior Pulmonary Embolism

NCT03729544
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
On-screen computerized decision support alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 21, 2026, 1:46 PM EDT
Recruiting No phase listed Observational

Pulmonary Hypertension Biorepository and Registry

NCT04808596
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jul 21, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jul 21, 2026, 1:46 PM EDT
Completed No phase listed Observational

Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism

NCT05568927
View directory record Official record
Conditions
Pulmonary Embolism, Chronic Thromboembolic Pulmonary Hypertension
Interventions
SEARCH algorithm
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Fresno, California • Irvine, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 21, 2026, 1:46 PM EDT
Recruiting No phase listed Observational

Pulmonary Hypertension Association Registry

NCT04071327
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Pulmonary Hypertension Association, Inc.
Other
Eligibility
0 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
52
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) Patients

NCT00747045
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, Acute Lung Injury
Interventions
Ventilation Strategy
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Jul 21, 2026, 1:46 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rutgers University Study of the Genetics of Pulmonary Hypertension

NCT07217522
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder), Pulmonary Arterial Hypertension of Congenital Heart Disease, Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
Interventions
Saliva sample, Health surveys
Genetic · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jul 21, 2026, 1:46 PM EDT
Completed No phase listed Observational

Thrombosis Outcomes in Pediatric Venous Thromboembolism

NCT03068923
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jul 21, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT01894022
View directory record Official record
Conditions
Hypertension
Interventions
Ambrisentan 5 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 21, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

NCT04523220
View directory record Official record
Conditions
End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
Interventions
BAY1213790 (Osocimab), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Azusa, California • Brawley, California • Encino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Jul 21, 2026, 1:46 PM EDT
Completed No phase listed Observational

PIMR and Pulmonary Vascular Disease

NCT05843461
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 21, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

NCT03195010
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematologic and Lymphocytic Disorder, Hematopoietic Cell Transplantation Recipient, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis, T-Cell Non-Hodgkin Lymphoma, Thrombocytopenia, Venous Thromboembolism
Interventions
Platelet Transfusion
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Jul 21, 2026, 1:46 PM EDT